BioLife Solutions, Inc. : BioLife Solutions 2011 Revenue Up 33%; Sixth Straight Quarter of Record Revenue

Solutions Inc.(), a leading developer, manufacturer,marketer of proprietary media for cellstissues, today announced preliminary record revenue for the fourth quarterfull calendar year 2011. Highlights include:

• Sixth consecutive quarter of record revenue
• Preliminary fourth quarter revenue of $809,000, up 13% over the third quarter41% over the same period in 2010
• Unaudited full year 2011 revenue of $2.8 million, an increase of 33% over 2010
• Distributor sales for the full year accounted for 20% of total revenue, up from 10% in 2010
• Revenue shipments to the regenerative medicine segment increased 50% over 2010
• Executed a new contract manufacturing agreement with profitable public life sciences company

Mike Rice, BioLife Chief Executive Officer, commented on the continued strong growth in revenue, "2011 was a very solid year for BioLife as we continued to execute our growth strategies. We have created a strong recurring revenue stream from an expanding foundation of customers in the biobanking, drug discoveryregenerative medicine markets. We have also secured,continue to pursue, new business opportunities to leverage our facilities, capacityexpertise. And in the fourth quarter of 2011, we executed non-exclusive agreements with several new distributors. All of these accomplishments should result in continued revenue growth in 2012."

®,® continued to displace home-brew biopreservation media formulations as customers increasingly recognize improved post-preservation celltissue viability enabled by the Company's proprietary technology.

"Both our presentnew customers are incorporating our cGMP, serum-free biopreservation media products into their researchproduction processes," Rice added.  "Our performance continues to demonstrate our commitment to growth,our ability to reduce our operating losses as we strive to reachsustain profitability."

BioLife Solutions will be exhibitingpresenting at the , January 30th - February 1st in Washington, DC.

About BioLife Solutions

BioLife Solutions develops, manufacturesmarkets patented hypothermic storagecryopreservation solutions for cells, tissues,organs.  The Company's proprietary HypoThermosol®CryoStor® platform of solutions are marketed to academiccommercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery,toxicology testing. BioLife's products are serum-freeprotein-free, fully defined,are formulated to reduce preservation-induced, delayed-onset cell damagedeath.  BioLife's enabling technology provides academicclinical researchers significant improvements in post-thaw cell, tissue,organ viabilityfunction.  For more information please visit ,follow BioLife on .

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectationsbeliefsare subject to numerous risksuncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the SecuritiesExchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

# # # #

Media Relations:	Investor Relations:
Len Hall	Matt Clawson
Allen & Caron Inc	Allen & Caron Inc
[phone]	[phone]
[e-mail]	[e-mail]